Celltrion Pharm Inc banner
C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 58 300 KRW 2.64% Market Closed
Market Cap: ₩2.6T

Celltrion Pharm Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celltrion Pharm Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
C
Celltrion Pharm Inc
KOSDAQ:068760
Revenue
₩536.4B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
22%
Yuhan Corp
KRX:000100
Revenue
₩2.2T
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
7%
SK Biopharmaceuticals Co Ltd
KRX:326030
Revenue
₩706.7B
CAGR 3-Years
42%
CAGR 5-Years
94%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Revenue
₩1.5T
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
2%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Revenue
₩231.8B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
6%
C
Caregen Co Ltd
KOSDAQ:214370
Revenue
₩72.8B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Pharm Inc
Glance View

Market Cap
2.6T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Intrinsic Value
25 822.63 KRW
Overvaluation 56%
Intrinsic Value
Price ₩58 300
C

See Also

What is Celltrion Pharm Inc's Revenue?
Revenue
536.4B KRW

Based on the financial report for Dec 31, 2025, Celltrion Pharm Inc's Revenue amounts to 536.4B KRW.

What is Celltrion Pharm Inc's Revenue growth rate?
Revenue CAGR 10Y
22%

Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Celltrion Pharm Inc have been 12% over the past three years , 18% over the past five years , and 22% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett